Annals of hematology · 2024
Clinical characteristics of membranous nephropathy after allogeneic hematopoietic stem cell transplantation: A real-world multicenter study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Yue, Zhao Peng, Zhang Yuan-Yuan, Ye Yi-Shan, Zhou Fang, Wan Ding-Ming, Chen Yi, Zhou Jian, Li Xin, Wang Yan, Liu Yue, Bian Zhi-Lei, Yang Kai-Qian, Li Zhen, Zhang Jian, Xu Wen-Wei, Zhou Jian-Ying, An Zhuo-Yu, Fu Hai-Xia, Chen Yu-Hong, Chen Qi, Wu Jin, Wang Jing-Zhi, Mo Xiao-Dong, Chen Huan, Chen Yao, Wang Yu, Chang Ying-Jun, Huang He, Huang Xiao-Jun, Zhang Xiao-Hui
Аннотация
Membranous nephropathy (MN) is a rare complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT). MN patients may develop nephrotic syndrome or even kidney failure, which greatly affects their quality of life and prognosis. However, current knowledge regarding MN after allo-HSCT is limited. Thus, a multicenter nested case‒control study was conducted. Patients who had been diagnosed with MN after allo-HSCT were retrospectively identified at 8 HSCT centers. A total of 51 patients with MN after allo-HSCT were included. The median age of MN patients after allo-HSCT was 38 years, and the median duration from HSCT to MN was 18 months. The use of HLA-matched donors (P = 0.0102) and peripheral blood as the graft source (P = 0.0060) were identified as independent predisposing risk factors for the onset of MN after allo-HSCT. Compared to those in the control group, the incidence of extensive chronic graft-versus-host disease was greater in the MN patients (P = 0.0002). A total of 31 patients developed nephrotic syndrome. Patients receiving combination treatments of corticosteroids and immunosuppressants appeared to have better outcomes. In conclusion, MN is a rare but occasionally severe complication following HSCT and may require active treatment.